Fulcrum Therapeutics Inc. (FULC)

Overview

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients suffering from genetically defined diseases with a significant unmet medical need. Established in 2015 with its headquarters located in Cambridge, Massachusetts, Fulcrum Therapeutics is at the forefront of developing innovative therapies. The company’s strategic focus lies in addressing rare neuromuscular, muscular, central nervous system, hematologic disorders, cardiomyopathies, and pulmonary diseases. Collaborating with industry leaders such as Acceleron Pharma Inc. and MyoKardia, Inc., Fulcrum is pushing the boundaries in drug discovery and development to modulate specific biological pathways for various targeted indications.

Products and Services

• Losmapimod:

A pioneering small molecule in phase III clinical trial specifically designed for the treatment of facioscapulohumeral muscular dystrophy. Losmapimod represents Fulcrum Therapeutics’ commitment to addressing the challenges in neuromuscular diseases by targeting the underlying genetic causes.

• Pociredir:

Identified as a fetal hemoglobin inducer presently in phase I clinical trial. Pociredir aims to provide a groundbreaking treatment for sickle cell disease and beta-thalassemia. By focusing on these blood disorders, Fulcrum is moving towards fulfilling the urgent need for new, effective treatments for these life-altering conditions.

• Drug Discovery for Rare Diseases:

In addition to its clinical trials for losmapimod and pociredir, Fulcrum Therapeutics is actively engaged in the discovery of drug targets for the treatment of a variety of rare disorders. These include neuromuscular, muscular, central nervous system, and hematologic disorders, along with genetic cardiomyopathies and pulmonary diseases. This effort underscores Fulcrum’s comprehensive approach to tackling complex, rare diseases by exploring and developing new therapeutic pathways.